Cabaletta Bio, Inc. (CABA) Stock Price & Analysis

Cabaletta Bio, Inc. (CABA) fell 0.29% to USD 3.47 as of September 8, 2026 at 05:48 UTC, according to Nexqual real-time market data.

CABA last closed at USD 3.48; the session ranged USD 3.4–3.6 on volume of 4,893,141 shares. Market capitalization is $588.32M, with a 52-week range of USD 1.63–4.23 (NMS). Source: Nexqual, September 8, 2026 at 05:48 UTC.

Key Statistics (as of September 8, 2026 at 05:48 UTC)

Technical Analysis (CABA)

Nexqual's technical model rates CABA "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 05:48 UTC.

Analyst Ratings (CABA)

Wall Street analysts rate CABA "Strong Buy" based on 8 analysts, with a mean price target of USD 13.25 (range USD 3–30), per Nexqual as of September 8, 2026 at 05:48 UTC.

From Cabaletta Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)

Key Strengths & Strategy (as disclosed to the SEC)

• Our proprietary CABA ® , or Cabaletta Approach to B cell Ablation platform, focuses on the CARTA approach.
• The confidentiality agreements are designed to protect our proprietary information and the invention assignment agreements are designed to grant us ownership of technologies that are developed for us by our employees, consultants or certain other third parties.
• Although we take steps to protect our proprietary information, including restricting access to our premises and our confidential information, as well as entering into agreements with our employees, consultants, advisors and potential collaborators, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information.

Partnerships

• In May 2023, we amended the LSA with Oxford to expand the license to include our rese-cel program for an upfront fee of $0.5 million and in August 2023, we entered into a vector supply agreement with Oxford, and a related second amendment to the LSA, for rese-cel with a total cost of up to approximately $5.0 million under the vector supply agreement.
• In addition, since 2023, we have partnered with Cellares Corporation, or Cellares, to incorporate automated manufacturing for rese-cel, which can enable scalability to produce rese-cel for thousands of patients per year with minimal capital investment, provide scheduling flexibility for rese-cel after commercialization and permit rapid expansion to support global expansion.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:48 UTC. This page is informational and not investment advice.